Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Factor of time in dendritic cell (DC) maturation : short-term activation of DCs significantly improves type 1 cytokine production and T cell responses
ID
Poženel, Primož
(
Author
),
ID
Zajc, Kaja
(
Author
),
ID
Švajger, Urban
(
Author
)
PDF - Presentation file,
Download
(3,43 MB)
MD5: 69F0E7A791E46A8047BF7B43E8A6B5A4
URL - Source URL, Visit
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05368-4
Image galllery
Abstract
Dendritic cells (DCs) have been intensively studied in correlation to tumor immunology and for the development DC-based cancer vaccines. Here, we present the significance of the temporal aspect of DC maturation for the most essential subsequent timepoint, namely at interaction with responding T cells or after CD40-Ligand restimulation. Mostly, DC maturation is still being achieved by activation processes which lasts 24 h to 48 h. We hypothesized this amount of time is excessive from a biological standpoint and could be the underlying cause for functional exhaustion. Indeed, shorter maturation periods resulted in extensive capacity of monocyte-derived DCs to produce inflammatory cytokines after re-stimulation with CD40-Ligand. This effect was most evident for the primary type 1 polarizing cytokine, IL-12p70. This capacity reached peak at 6 h and dropped sharply with longer exposure to initial maturation stimuli (up to 48 h). The 6 h maturation protocol reflected superiority in subsequent functionality tests. Namely, DCs displayed twice the allostimulatory capacity of 24 h- and 48 h-matured DCs. Similarly, type 1 T cell response measured by IFN-γ production was 3-fold higher when CD4$^+$ T cells had been stimulated with shortly matured DC and over 8-fold greater in case of CD8$^+$ T cells, compared to longer matured DCs. The extent of melanoma-specific CD8$^+$ cytotoxic T cell induction was also greater in case of 6 h DC maturation. The major limitation of the study is that it lacks in vivo evidence, which we aim to examine in the future. Our findings show an unexpectedly significant impact of temporal exposure to activation signals for subsequent DC functionality, which we believe can be readily integrated into existing knowledge on in vitro/ex vivo DC manipulation for various uses. We also believe this has important implications for DC vaccine design for future clinical trials.
Language:
English
Keywords:
dendritic cells
,
maturation
,
vaccines
,
cytotoxic T cells
,
cancer
,
anti-tumor responses
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 14 str.
Numbering:
Vol. 22, art. 541
PID:
20.500.12556/RUL-158422
UDC:
615.371:616-006
ISSN on article:
1479-5876
DOI:
10.1186/s12967-024-05368-4
COBISS.SI-ID:
198061059
Publication date in RUL:
10.06.2024
Views:
301
Downloads:
56
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of translational medicine
Shortened title:
J. transl. med.
Publisher:
BioMed Central
ISSN:
1479-5876
COBISS.SI-ID:
513978393
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
dendritične celice
,
zorenje
,
citotoksične celice T
,
protitumorski odzivi
,
rak (medicina)
,
cepiva
Projects
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
J1-4417
Name:
Razvoj novih nizkomolekularnih modulatorjev Tollu podobnih receptorjev 7 in 8 za imunoterapijo raka
Funder:
ARIS - Slovenian Research and Innovation Agency
Project number:
P3-0371
Name:
Človeške matične celice-napredno zdravljenje s celicami III
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back